First institutional discussion on the future of Sifi, the Italian Pharmaceutical Industry Company with a factory in Aci Sant’Antonio, in the Catania area, considered one of the technological and industrial excellences of the Etna area and today part of the Spanish Faes Farma group. At the center of the meeting held today between the Ministry of Business and Made in Italy, the Ministry of Health and company top management, the industrial plan of the Sicilian site, future investments and the framework of assessments connected to the golden power procedures, which concern strategic sectors, including the pharmaceutical one.
The comparison reportedly revealed the company’s confirmation of the continuity of the industrial path already announced. Sifi has in fact reiterated that there have been no deviations from the objectives and strategies outlined in recent months and has renewed its desire to continue with the planned investments, consolidating its presence in Sicily and the productive role of the Etna site.
An important passage also concerns the group’s growth prospects. The company has indicated among its strategic objectives the doubling of Faes Farma’s turnover by 2030 compared to 2024 levels, with the goal of one billion euros in sales. A target that Mimit considered significant, underlining the hope that this trajectory can also translate into concrete effects on the turnover and operations of the Italian factories, destined to remain central in the development of the group’s ophthalmology centre.
On the employment front, one of the most sensitive issues in the dossier, it was confirmed that the number of redundancies dropped from the initial 52 units to 39 overall. The exits, it was specified, occurred on a voluntary basis, after the approval of the proposed agreement by the Sifi workers’ assembly.
The ministry, in agreement with the Department of Health, has finally indicated the need for the discussion started today not to remain an isolated episode but to become a stable working method between institutions and businesses. The objective is to accompany with constant monitoring a sector considered strategic for the country, such as the pharmaceutical sector, in a phase in which innovation, industrial control and protection of national assets return to the center of industrial policy.
